Mostrar el registro sencillo del ítem

dc.contributor.authorRomero Sanz, Silvia
dc.contributor.authorCaldero Escudero, Elena
dc.contributor.authorÁlvarez Illera, María Pilar
dc.contributor.authorSanto Domingo Mayoral, Jaime 
dc.contributor.authorFonteriz García, Rosalba Inés 
dc.contributor.authorMontero Zoccola, María Teresa 
dc.contributor.authorÁlvarez Martín, Javier 
dc.date.accessioned2024-02-09T11:30:20Z
dc.date.available2024-02-09T11:30:20Z
dc.date.issued2023
dc.identifier.citationFrontiers in Pharmacology, 2023, vol. 14, 1182428es
dc.identifier.issn1663-9812es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/66076
dc.descriptionProducción Científicaes
dc.description.abstractIntroduction: The high prevalence of neurodegenerative diseases in our population and the lack of effective treatments encourage the search for new therapeutic targets for these pathologies. We have recently described that submaximal inhibition of the Sarco-Endoplasmic Reticulum Ca2+ ATPase (SERCA), the main responsible for ER calcium storage, is able to increase lifespan in Caenorhabditis elegans worms by mechanisms involving mitochondrial metabolism and nutrient-sensitive pathways. Methods: We have studied here the effects of submaximal SERCA inhibition in a chemicalmodel of Parkinson’s disease (PD) induced in C. elegansworms by treatment with themitochondrial complex I inhibitor rotenone. For specific SERCA inhibition,we treated worms with RNAi against sca-1, the sole orthologue of SERCA in C. elegans. Results and Discussion: Our results show that rotenone produces alterations in worms that include decreased lifespan, smaller size, reduced fertility, decreased motility, defecation and pumping rate, increased mitochondrial ROS production, reduced mitochondrial membrane potential and oxygen consumption rate, altered mitochondrial structure, and altered ethanol preference in behavioral studies. Most of these alterations were either fully or partially reversed in worms treated with sca-1 RNAi, suggesting that SERCA inhibition could be a novel pharmacological target in the prevention or treatment of neurodegeneration.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherFrontierses
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.classificationC. eleganses
dc.subject.classificationrotenone
dc.subject.classificationParkinson’s disease
dc.subject.classificationSERCA
dc.subject.classificationlifespan
dc.subject.classificationendoplasmic reticulum
dc.subject.classificationmitochondria
dc.subject.classificationCa2+ signaling
dc.titleSERCA inhibition improves lifespan and healthspan in a chemical model of Parkinson disease in Caenorhabditis eleganses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2023 The Authors
dc.identifier.doi10.3389/fphar.2023.1182428es
dc.relation.publisherversionhttps://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1182428/fulles
dc.identifier.publicationtitleFrontiers in Pharmacologyes
dc.identifier.publicationvolume14es
dc.peerreviewedSIes
dc.description.projectMICINN BFU 2017-83509-Res
dc.description.projectMICINN PID 2021-122239OB-I00es
dc.identifier.essn1663-9812es
dc.rightsAttribution 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco2411.99 Otrases
dc.subject.unesco3209.99 Otrases


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem